What drove today’s move in 4564.T stock

Today’s fall in **4564.T stock** to **JPY 22.00** was driven by heavy trading ahead of the company earnings on **2026-01-30** and ongoing clinical-program news. Volume spiked to **35,304,800.00**, indicating short-term repositioning by institutional and retail traders.

Is 4564.T stock a buy after the drop

Given current fundamentals, Meyka AI assigns **4564.T stock** a Grade B and a HOLD suggestion; cash per share is **JPY 5.26** but EPS is negative (**-2.83**). Buying depends on risk tolerance, clinical outlook, and willingness to accept trial binary risk.

What are the main catalysts for 4564.T stock soon

Primary catalysts for **4564.T stock** are the upcoming earnings on **2026-01-30** and any Phase III or licensing updates for S-588410 and other programs. Positive trial or deal news would likely drive meaningful upside on the JPX.

JP Stocks

4564.T OncoTherapy Science (JPX) falls to JPY 22.00 Jan 14, 2026: Earnings ahead

ByHuzaifa Zahoor January 14, 2026

4564.T stock fell -8.33% to JPY 22.00 on 14 Jan 2026, making it one of the JPX’s most active names by volume today. Trading volume hit 35,304,800.00 shares against an average of 58,329,469.00, reflecting heavy intraday flows as traders reposition ahead of a scheduled earnings announcement on 2026-01-30. The move ties directly to clinical development headlines and valuation re-rating in the Healthcare sector in Japan.